Scorpius Holdings Launches Scorpius Ventures to Support Biotech Onshoring with Hybrid Model

• Scorpius Ventures launched as a new business unit to support emerging biotech companies with U.S.-based onshoring of biologic production.

• The hybrid model combines service fees with equity investment, reducing financial barriers for biotech companies and fostering shared success.

Scorpius Holdings, Inc. (NYSE American: SCPX) has announced the launch of a new business unit, Scorpius Ventures, which will help emerging biotech companies onshore the production of biologics. This initiative is designed to ease financial constraints for biotech firms by combining service fees with an equity stake in their operations.

The new unit will offer a capital-efficient pathway to access Scorpius’ cGMP (current Good Manufacturing Practice) manufacturing services, providing biotech companies with the resources needed to develop and produce critical therapies. According to Jeff Wolf, CEO of Scorpius Holdings, the hybrid fee-and-equity model fosters a partnership approach that benefits both Scorpius and its clients. “We’re committed to enabling biotech innovation by reducing financial obstacles and creating true partnerships,” he said.

Scorpius Ventures aligns with the BIOSECURE Act, which aims to strengthen U.S. biosecurity and support the onshoring of essential biological production. By prioritising U.S.-based manufacturing, Scorpius Ventures seeks to improve supply chain stability and contribute to job growth within the domestic economy. The company’s model also allows biotech firms to leverage Scorpius’ manufacturing expertise and industry-leading CMC services, helping them streamline development and reduce risks.

In addition to enhancing operational capabilities, the venture model allows biotech clients to access fundraising support, potentially facilitating their broader capital-raising efforts. With this launch, Scorpius Ventures is positioning itself as a key player in reshaping how emerging biotech companies navigate manufacturing challenges while strengthening the U.S. biomanufacturing sector.